盐酸苯海索结构式
|
常用名 | 盐酸苯海索 | 英文名 | Benzhexol hydrochloride |
|---|---|---|---|---|
| CAS号 | 52-49-3 | 分子量 | 337.927 | |
| 密度 | N/A | 沸点 | 447.9ºC at 760mmHg | |
| 分子式 | C20H32ClNO | 熔点 | 258.5ºC | |
| MSDS | N/A | 闪点 | 211ºC |
盐酸苯海索用途Trihexyphenidyl盐酸盐是抗毒蕈碱类的抗帕金森剂, 结合至M1毒蕈碱受体。 |
| 中文名 | 盐酸苯海索 |
|---|---|
| 英文名 | Benzhexol hydrochloride |
| 中文别名 | 盐酸三己芬迪 | 1-环己基-1-苯基-3-(1-哌啶基)-丙醇盐酸盐 |
| 英文别名 | 更多 |
| 沸点 | 447.9ºC at 760mmHg |
|---|---|
| 熔点 | 258.5ºC |
| 分子式 | C20H32ClNO |
| 分子量 | 337.927 |
| 闪点 | 211ºC |
| 精确质量 | 337.217255 |
| PSA | 23.47000 |
| LogP | 5.07040 |
| InChIKey | QDWJJTJNXAKQKD-UHFFFAOYSA-N |
| SMILES | Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1 |
| 外观性状 | solid | white |
| 储存条件 | 通风低温干燥; 与库房食品原料分开存放。 |
| 水溶解性 | H2O: soluble |
| 计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:2 4.可旋转化学键数量:5 5.互变异构体数量:无 6.拓扑分子极性表面积23.5 7.重原子数量:23 8.表面电荷:0 9.复杂度:314 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:1 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:2 |
| 海关编码 | 2933399090 |
|---|---|
| 中文概述 | 2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
| 申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Gingival pain: an unusual side effect of ziprasidone.
BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... |
|
|
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)
|
|
|
DYT16: the original cases.
J. Neurol. Neurosurg. Psychiatr. 83(10) , 1012-4, (2012) DYT16 is an autosomal recessive dystonia-parkinsonism due to putative mutations at PRKRA gene. The aim of this study was to describe clinical features providing video documentation of patients with DY... |
| 1-(3-cyclohexyl-3-hydroxy-3-phenylpropyl)piperidinium chloride |
| 1-Cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-olhydrochlorid |
| Trihexy |
| 1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride (1:1) |
| UNII:AO61G82577 |
| 1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-olhydrochlorid |
| 1-cyclohexyl-1-phenyl-3-(1-piperidinyl)-1-propanol hydrochloride |
| 1-Piperidinepropanol, α-cyclohexyl-α-phenyl-, hydrochloride (1:1) |
| pacitane |
| Broflex |
| (-)-α-Cyclohexyl-α-phenyl-1-piperidinepropanol hydrochloride |
| 1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol hydrochloride |
| pipanol |
| 1-Cyclohexyl-1-phenyl-3-(1-piperidinyl)-1-propanol hydrochloride (1:1) |
| tremin |
| EINECS 205-614-4 |
| Benzhexol HCL |
| Parkan |
| paralest |
| peragit |
| Sedrina |
| (+)-α-Cyclohexyl-α-phenyl-1-piperidinepropanol hydrochloride |
| cyclodol |
| a-Cyclohexyl-a-phenyl-1-piperidinepropanol Hydrochloride |
| MFCD00058212 |
| trihexylphenidyl HCl |
| 1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride |
| 1-cyclohexyl-1-phényl-3-pipéridin-1-ylpropan-1-ol chlorhydrate |
| D,L-Trihexyphenidyl Hydrochloride |
| Trihexyphenidyl hydrochloride |